These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 529617)

  • 21. [Serial changes of lymphocyte subpopulations, anti-T cell antibodies, and circulating immune complexes in patients with lupus nephritis, nephrotic syndrome and poststreptococcal acute glomerulonephritis (author's transl)].
    Nakabayashi K; Yoshida M; Nagasawa T
    Nihon Jinzo Gakkai Shi; 1981 Mar; 23(3):253-63. PubMed ID: 6975844
    [No Abstract]   [Full Text] [Related]  

  • 22. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoglobulin in clinically uninvolved skin in systemic lupus erythematosus: association with renal disease.
    Gilliam JN; Cheatum DE; Hurd ER; Stastny P; Ziff M
    J Clin Invest; 1974 May; 53(5):1434-40. PubMed ID: 4596508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-DNA antibodies in systemic lupus erythematosus (author's transl)].
    Clotet B; Ruibal A; Pigrau C; Murcia C; Pahissa A; Lience E
    Med Clin (Barc); 1982 Feb; 78(4):128-131. PubMed ID: 6978438
    [No Abstract]   [Full Text] [Related]  

  • 25. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunological tests in the diagnosis and prognosis of disseminated lupus erythematosus, before treatment (author's transl)].
    Tron F; Bach JF
    Nouv Presse Med; 1977 Sep; 6(29):2573-8. PubMed ID: 302934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical and immunological studies on the exacerbation of systemic lupus erythematosus (author's transl)].
    Komeji S; Kitamura M; Kashiwazaki S
    Nihon Naika Gakkai Zasshi; 1982 Apr; 71(4):448-57. PubMed ID: 7108329
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical significance of the lupus band test in systemic lupus erythematosus (author's transl)].
    Yasue T
    Nihon Hifuka Gakkai Zasshi; 1980 Sep; 90(10):901-7. PubMed ID: 7012400
    [No Abstract]   [Full Text] [Related]  

  • 29. Membranous glomerulopathy in systemic lupus erythematosus.
    Gonzalez-Dettoni H; Tron F
    Adv Nephrol Necker Hosp; 1985; 14():347-64. PubMed ID: 3919538
    [No Abstract]   [Full Text] [Related]  

  • 30. [Activity of the complement system in nephropathies of childhood].
    Zelazko ME; Feldman G
    Medicina (B Aires); 1977; 37(3):205-14. PubMed ID: 895495
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical significance of hemolytic complement activity via classical pathway].
    Takemura S; Kondo M
    Nihon Rinsho; 1990 Feb; 48 Suppl():634-6. PubMed ID: 2355588
    [No Abstract]   [Full Text] [Related]  

  • 32. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.
    Falk RJ; Dalmasso AP; Kim Y; Lam S; Michael A
    N Engl J Med; 1985 Jun; 312(25):1594-9. PubMed ID: 4000197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered complement component C3A (beta-1C--beta-1A) in patients with glomerulonephritis.
    Soothill JF
    Clin Exp Immunol; 1967 Jan; 2(1):83-92. PubMed ID: 4166187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [T-suppressor functional activity in systemic lupus erythematosus and chronic glomerulonephritis].
    Gordovskaia NB; Denisov VN; Krasnova TN
    Ter Arkh; 1982; 54(7):29-32. PubMed ID: 6215736
    [No Abstract]   [Full Text] [Related]  

  • 35. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
    Welch TR; Forristal J; Beischel L
    J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biological characteristics and pathological significance of alternative pathway].
    Mikami A; Kohno M; Chimoto T
    Nihon Rinsho; 1979 May; 37(5):1011-6. PubMed ID: 381715
    [No Abstract]   [Full Text] [Related]  

  • 37. Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.
    Andres GA; Accinni L; Beiser SM; Christian CL; Cinotti GA; Erlanger BF; Hsu KC; Seegal BC
    J Clin Invest; 1970 Nov; 49(11):2106-18. PubMed ID: 4097660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The complement system and clinical effects of its disorders].
    Siegert CE; van Es LA; Daha MR
    Ned Tijdschr Geneeskd; 1996 Nov; 140(46):2268-73. PubMed ID: 8984378
    [No Abstract]   [Full Text] [Related]  

  • 39. [Circulating immune complexes and C3 in patients with systemic lupus erythematosus. The relationship between clinical manifestations and nephropathy (author's transl)].
    Rodríguez-Valverde V; Peña Sagredo JL; Orte Martínez J; Novo Fernández MJ; Sánchez Andrada S; Sampedro Alvarez J
    Med Clin (Barc); 1982 May; 78(9):353-7. PubMed ID: 6808263
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune complexes and connective tissue disease.
    Kaplan AP
    Bull N Y Acad Med; 1981 Sep; 57(7):638-49. PubMed ID: 6456027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.